+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The 5-HT₆ serotonin receptor antagonist SB-271046 attenuates the development and expression of nicotine-induced locomotor sensitisation in Wistar rats



The 5-HT₆ serotonin receptor antagonist SB-271046 attenuates the development and expression of nicotine-induced locomotor sensitisation in Wistar rats



Neuropharmacology 61(3): 451-457



5-HT(6) receptors are almost exclusively expressed in the central nervous system, particularly in areas relevant for addictive behaviour. Based on this, together with other data, this receptor may be a viable target for the control of drug abuse. The present study tested the ability of the 5-HT(6) receptor antagonist SB-271046 to attenuate the development and expression of nicotine-induced behavioural sensitisation. Rats were habituated to the test apparatus prior to experimentation (day 0) and locomotor activity recorded. On days 1 and 5, animals were placed in locomotor test apparatus and after 30 min injected with SB-271046 (1, 3, and 6 mg/kg, intraperitoneally IP) or vehicle. Thirty minutes later, nicotine (0.4 mg/kg, subcutaneously SC) or saline were administered and activity recorded for 60 min. On days 2, 3 and 4 treatments were performed in the home cage. After 17 days of withdrawal (day 23), a challenge test was performed with nicotine (0.4 mg/kg SC) or saline. In a separate experiment of similar design the effects of SB-271046 (1, 3, and 6 mg/kg IP) was tested for its ability to reduce the expression of behavioural sensitisation (day 23). SB-271046 dose dependently reduced the development and expression of nicotine sensitisation vs respective controls. In conclusion, the 5-HT(6) receptor antagonist SB-271046 reduced both the development and expression of nicotine sensitisation, suggesting that the 5-HT(6) receptor may be a viable target for the control of nicotine abuse. Further studies are warranted to substantiate this conclusion and further understand the role of 5-HT(6) receptors in addiction.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056160688

Download citation: RISBibTeXText

PMID: 21329711

DOI: 10.1016/j.neuropharm.2011.01.045


Related references

A novel highly selective 5-HT6 receptor antagonist attenuates ethanol and nicotine seeking but does not affect inhibitory response control in Wistar rats. Behavioural Brain Research 236(1): 157-165, 2013

The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice. European Journal of Pharmacology 428(1): 97, 2001

The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice. European Journal of Pharmacology 428(1): 97-103, 28 September, 2001

Mirtazapine attenuates the expression of nicotine-induced locomotor sensitization in rats. European Journal of Pharmacology 812: 28-37, 2017

Pharmacologic antagonism of ghrelin receptors attenuates development of nicotine induced locomotor sensitization in rats. Regulatory Peptides 172(1-3): 77-80, 2011

C-Fos expression patterns induced in the rat brain by clozapine, haloperidol and the selective 5-HT6 receptor antagonist SB-271046. British Journal of Pharmacology 128(PROC Suppl. ): 159P, 1999

The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats. European Neuropsychopharmacology 20(10): 731-746, 2010

The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. Plos one 8(10): E77284, 2013

Clozapine inhibits development and expression of nicotine-induced locomotor sensitization in rats. Synapse 63(1): 15-21, 2008

Effects of risperidone on development and expression of nicotine-induced locomotor sensitization in rats. Synapse 65(8): 708-714, 2011

M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20(4): 311-321, 1999

Clozapine attenuates the locomotor sensitisation and the prepulse inhibition deficit induced by a repeated oral administration of Catha edulis extract and cathinone in rats. Behavioural Brain Research 160(2): 365-373, 2005

Attenuated methamphetamine-induced locomotor sensitization in serotonin transporter knockout mice is restored by serotonin 1B receptor antagonist treatment. Behavioural Pharmacology 26(1-2): 167-179, 2015

Wistar Kyoto and Wistar rats differ in the affective and locomotor effects of nicotine. Physiology and Behavior 93(1-2): 177-188, 2008

Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats. Pharmacology Biochemistry and Behavior 74(2): 279-286, 2003